This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2024 Aug;212(2):266.

doi: 10.1097/JU.0000000000004021. Epub 2024 May 8.

Editorial Comment

Roger Dmochowski¹

Affiliations

PMID: 38716839
DOI: 10.1097/JU.0000000000004021

Editorial

Editorial Comment

Roger Dmochowski. J Urol. 2024 Aug.

. 2024 Aug;212(2):266.

doi: 10.1097/JU.0000000000004021. Epub 2024 May 8.

Author

Roger Dmochowski¹

Affiliation

¹ Vanderbilt University Medical Center, Nashville, Tennessee.

PMID: 38716839
DOI: 10.1097/JU.0000000000004021

No abstract available

PubMed Disclaimer

Comment on

Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.
Staskin D, Owens-Grillo J, Thomas E, Rovner E, Cline K, Mujais S. Staskin D, et al. J Urol. 2024 Aug;212(2):256-266. doi: 10.1097/JU.0000000000003999. Epub 2024 May 6. J Urol. 2024. PMID: 38708869 Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources